143 results on '"Vioix, H."'
Search Results
2. CO168 A Propensity Score-Based Comparison of Tepotinib Versus Immunotherapy with/without Chemotherapy, Using Real-World Data in Previously Untreated Met Exon 14 (METEX14) Skipping Non-Small Cell Lung Cancer (NSCLC)
3. SA22 Tepotinib Versus Chemotherapy in Met Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC): Real-World Evidence (RWE) and Matching-Adjusted Indirect Comparison (MAIC) to Explore the Impact of Subsequent Therapy
4. EP12.01-59 Tepotinib and Capmatinib in Patients with MET exon 14 Skipping NSCLC: A Matching Adjusted Indirect Comparison (MAIC)
5. P2.11-02 Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION
6. CO58 Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib With Capmatinib in Previously Treated Advanced Non-Small Cell Lung Cancer (aNSCLC) With MET Exon 14 (METex14) Skipping
7. CO23 Validating the Results of a Matching Adjusted Indirect Comparison (MAIC) in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC)
8. EE447 Budget Impact Analysis of Tepotinib in England for Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC) Harboring MET Exon 14 (METex14) Skipping
9. PCR153 A Comparison of Utility Values Generated Using Different Methods From the Phase II Vision Trial of Tepotinib for Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 (METex14) Skipping
10. CO94 Tepotinib Compared With Chemoimmunotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC): Matching Adjusted Indirect Comparison (MAIC) of VISION in MET Exon 14 (METex14) Skipping NSCLC and KEYNOTE-189 in Wild-type NSCLC
11. RWD51 Demonstrating Internal and External Validity in Real-World Datasets: A Case Study in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC)
12. 321MO Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION
13. 1180P Treatment patterns and progression-free survival in MET exon 14 (METex14) skipping advanced non-small cell lung cancer (aNSCLC) in real-world clinical practice
14. EE160 Tepotinib for the Treatment of Adult Patients with Metastatic Non-Small Cell Lung Cancer Harboring METEX14 Skipping Alterations: A US Cost-Effectiveness Analysis
15. 1255P Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
16. 1381P TOGETHER: Pooled real-world datasets of METex14 skipping NSCLC and adjusted comparison of upfront (chemo-)immunotherapy with tepotinib from VISION
17. PCN113 Prevalence of MET exon 14 (METex14) Skipping in Patients with Advanced NSCLC: A Systematic Literature Review
18. 159P Clinical characteristics of patients with advanced NSCLC and MET exon 14 (METex14) skipping: A systematic literature review
19. 158P Prevalence and clinical outcomes of MET exon 14 (METex14) skipping in patients with advanced NSCLC: A systematic literature review
20. PATH01.01 Diagnostic and Economic Value of Next-Generation Sequencing (NGS) in Genotyping Non-Small Cell Lung Cancer Tumors (NSCLC): A Literature Review
21. MO01.45 Health-Related Quality of Life (HRQoL) in Patients with NSCLC Harboring MET Exon 14 Skipping (METex14) Treated with Tepotinib
22. PATH01.02 Diagnostic and Economic Value of Liquid vs. Solid Tissue Biopsy Procedures for the Detection of Targetable Mutations in Non-Small Cell Lung Cancer (NSCLC) Tumors: A Literature Review
23. EE146 Cost-effectiveness of Tepotinib for Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Harboring Metex14 Skipping Alterations in Spain
24. PRS18 The Clinical and Cost IMPACT of Adherence to Chronic Obstructive Pulmonary Disease Guideline Recommendations in England: A Cost Consequence MODEL
25. 1347P Health-related quality of life (HRQoL) in patients (pts) with NSCLC harboring MET exon 14 skipping (METex14) treated with tepotinib
26. Protocol for a systematic literature review and network meta-analysis of the clinical benefit of inhaled maintenance therapies in chronic obstructive pulmonary disease (COPD)
27. PCN64 COST-EFFECTIVENESS ANALYSIS OF SORAFENIB VERSUS BEST SUPPORTIVE CARE (BSC) IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC): THE PUBLIC HEALTH CARE SYSTEM PERSPECTIVE IN BRAZIL
28. Demonstrating the cost effectiveness of Movantik for the treatment of opioid induced constipation in Patients with inadequate response to Laxatives; a UK perspective
29. Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective
30. Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
31. The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective
32. Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
33. Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective
34. Cost-Effectiveness of Saxagliptin Compared To Glp-1 Analogues As An Add-On To Insulin in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
35. Cost-Minimisation Analysis of Saxagliptin Compared to Sitagliptin And Linagliptin As Triple Therapy In Combination With Metformin And A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
36. Cost-Minimisation Analysis of Dapagliflozin Compared To Lixisenatide As An Add-On To Insulin In The Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
37. Three Years of the Gefitinib UK Single Patient Access (SPA) Scheme: Duration of Treatment for Patients with EGFR Mutation Positive NSCLC in NHS Clinical Practice
38. PCN132 Duration of Gefitinib Treatment in EGFR Mutation Positive NSCLC Patients in a UK Single Payement Access Scheme (SPA)
39. PSY36 - Demonstrating the cost effectiveness of Movantik for the treatment of opioid induced constipation in Patients with inadequate response to Laxatives; a UK perspective
40. PSY38 COST-EFFECTIVENESS OF GOLIMUMAB IN ANKYLOSING SPONDYLITIS FROM THE UK PAYER PERSPECTIVE
41. PCN70 COST EFFECTIVENESS ANALYSIS OF SUNITINIB, BEVACIZUMAB + INTERFERON-ALFA AND TEMSIROLIMUS AS FIRST-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN SWEDEN
42. PDB87 - Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
43. PDB98 - Cost-Minimisation Analysis of Saxagliptin Compared to Sitagliptin And Linagliptin As Triple Therapy In Combination With Metformin And A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
44. PDB95 - Cost-Minimisation Analysis of Dapagliflozin Compared To Lixisenatide As An Add-On To Insulin In The Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
45. PDB88 - Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
46. PDB89 - Cost-Effectiveness of Saxagliptin Compared To Glp-1 Analogues As An Add-On To Insulin in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
47. PDB73 - Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective
48. PDB67 - Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective
49. PDB66 - The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective
50. PCN186 - Three Years of the Gefitinib UK Single Patient Access (SPA) Scheme: Duration of Treatment for Patients with EGFR Mutation Positive NSCLC in NHS Clinical Practice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.